Tangram Therapeutics

Relentless medicine discovery.

Founded 2003

London, United Kingdom 32 employees Venture round Total: $130.90M Biotechnology, Health Care

General Information

Company Name Tangram Therapeutics

Founded Year 2003

Location

London, United Kingdom

Employees 32

Industries Biotechnology, Health Care

Funding Stage Venture round

Business Model B2B, B2B2C

Revenue Model Licensing, Product Sales, Service Fee

Social

BounceWatch is an independent company data service, not affiliated with Tangram Therapeutics. To contact Tangram Therapeutics, visit etherapeutics.co.uk.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tangram Therapeutics compare?

A PDF of Tangram Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tangram Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Tangram Therapeutics on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

United Kingdom Market

Market Signals All Companies

Biotechnology

Industry Signals All Companies in United Kingdom

Tangram Therapeutics Alternatives

All Signals Trend Reports

AI Insight

Bounce Watch AI

1 month ago

Tangram Therapeutics recently secured a significant £28.90M Venture Round, demonstrating renewed investor confidence in its RNAi and computational drug discovery platforms. This substantial capital infusion is complemented by the strategic appointment of a Chief Development Officer, planned for late 2026, signaling a clear intent to accelerate its pipeline and advance novel therapeutics through clinical development. The company is strategically positioning itself for intensified R&D and product advancement in the innovative medicines space.

Signal Types

Funding Hiring

Strategic Labels

Growth Funding Executive Leadership Pipeline Acceleration

Next Move: Pipeline Advancement

Impact: 8/10

Ideal For: Biotech Growth Equity VCs — Drug Development

About Tangram Therapeutics

Tangram Therapeutics, formerly known as e-therapeutics, is a dynamic biotechnology startup founded in 2003 and headquartered in the United Kingdom. Touting the slogan, "Relentless medicine discovery," the company is dedicated to revolutionizing the field of healthcare by integrating computation, RNAi, and innovative thinking to expedite the development of superior medicines.

The firm operates at the intersection of the Biotechnology and Health Care industries, emphasizing a unique approach that promises not only to accelerate discovery timelines but also to enhance medicinal outcomes. Such a strategy positions Tangram Therapeutics as a distinguished player in medical innovation.

In its latest financial milestone, the company secured a substantial £28.90M during a Venture Round investment made on 03 July 2024, with notable participation from M&G Investments and Richard Griffith.

Business keywords: Biotech, Drug Discovery, RNA Interference, Computational Biology, Medicine Development, Proprietary Computational Systems, Drug Candidate Optimization, Efficacy Prediction, Side Effect Minimization, Cell Interaction Analysis, Unconventional Thinking, Innovation in Medicine, Fast Drug Development, Tangram Therapeutics

Services & Products

Development of RNAi medicines

Computational drug discovery

Clinical trials for new therapeutics

Exploration of novel biological targets

Target Customers

Healthcare providers Patients with unmet medical needs Pharmaceutical companies Biotechnology investors

Funding Rounds & Investors (5)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	£28.90M	2	M&G Investments, Richard Griffith	03 Jul 2024
Post IPO Equity	$13.50M	1	M&G plc	30 Sep 2022
Post IPO Equity	£22.50M	-		14 May 2021
Post IPO Equity	$64.00M	-		11 Feb 2013
Post IPO Equity	£2.00M	1	Octopus Ventures	18 Mar 2009

Tangram Therapeutics Alternatives & Competitors

View All Alternatives

Tangram Therapeutics vs

Serina Therapeutics, Inc. United States

We have the next generation in polymer therapeutics. Go to www.serinatherapeutics.com and explore ou...

Grant

15 employees

Biopharma, Biotechnology

Compare Tangram Therapeutics vs Serina Therapeutics, Inc.

Tangram Therapeutics vs

Emulate, Inc. United States

Our Organ-on-a-Chip technology provides a high-fidelity window into the inner workings of human biol...

Series F

71 employees

Biotechnology, Health Care

Compare Tangram Therapeutics vs Emulate, Inc.

Tangram Therapeutics vs

PROTEINA Korea South

Our Protein-protein interaction (PPI) analysis platform enables quantitative measurements at the sin...

Series C

32 employees

Biotechnology, Health Care

Compare Tangram Therapeutics vs PROTEINA

View all alternatives

FAQ About Tangram Therapeutics

Relentless medicine discovery.

Tangram Therapeutics was founded in 2003.

Tangram Therapeutics is headquartered in London, United Kingdom.

Tangram Therapeutics operates in Biotechnology and Health Care. Its work centres on Biotech, Drug Discovery, RNA Interference and Computational Biology. Its customers include Healthcare providers, Patients with unmet medical needs and Pharmaceutical companies.

Tangram Therapeutics has a B2B and B2B2C business model. Its revenue comes from Licensing, Product Sales and Service Fee.

Tangram Therapeutics has approximately 32 employees.

Tangram Therapeutics has completed 5 funding rounds, raising a total of $130.90M. The latest funding stage is Venture round.

Tangram Therapeutics offers: Development of RNAi medicines, Computational drug discovery, Clinical trials for new therapeutics, Exploration of novel biological targets.

Top alternatives and competitors to Tangram Therapeutics include Serina Therapeutics, Inc., Emulate, Inc., PROTEINA, Flexus Biosciences, Wuhan YZY Biopharma Co. Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Tangram Therapeutics and Serina Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tangram Therapeutics, https://bouncewatch.com/company/e-therapeutics-plc, updated 21 September 2026. When citing, please name BounceWatch and link this page.